Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

Article  Google Scholar 

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531.

Article  CAS  PubMed  Google Scholar 

Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/s0140-6736(18)32557-1.

Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20. https://doi.org/10.1056/NEJMoa072252.

Article  CAS  PubMed  Google Scholar 

Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. https://doi.org/10.1016/s0140-6736(11)61873-4.

Article  CAS  PubMed  Google Scholar 

Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304. https://doi.org/10.1200/jco.18.01138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim TH, Kim IH, Kang SJ, et al. Korean practice guidelines for gastric cancer 2022: an evidence-based multidisciplinary approach. J Gastric Cancer. 2023;23:3–106. https://doi.org/10.5230/jgc.2023.23.e11.

Article  PubMed  PubMed Central  Google Scholar 

Japanese Gastric Cancer Association jgca@ koto. kpu-m. ac. jp. Japanese gastric cancer treatment guidelines. Gastric Cancer. 2021;24:1–21. https://doi.org/10.1007/s10120-020-01042-y.

Article  Google Scholar 

Allum W, Lordick F, Alsina M, et al. ECCO essential requirements for quality cancer care: oesophageal and gastric cancer. Crit Rev Oncol Hematol. 2018;122:179–93. https://doi.org/10.1016/j.critrevonc.2017.12.019.

Article  PubMed  Google Scholar 

Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13. https://doi.org/10.1200/jco.20.02914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. https://doi.org/10.1056/NEJMoa1112088.

Article  PubMed  Google Scholar 

Nakanishi K, Kanda M, Ito S, et al. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset. Gastric Cancer. 2019;22:1215–25. https://doi.org/10.1007/s10120-019-00961-9.

Article  CAS  PubMed  Google Scholar 

Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309–18. https://doi.org/10.1016/s1470-2045(15)00553-7.

Article  CAS  PubMed  Google Scholar 

Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081–92. https://doi.org/10.1016/s1470-2045(21)00297-7.

Article  CAS  PubMed  Google Scholar 

Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373–8. https://doi.org/10.1093/annonc/mdu146.

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Niedzwiecki D, Mamon HJ, et al. adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (alliance). J Clin Oncol. 2017;35:3671–7. https://doi.org/10.1200/jco.2017.74.2130.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang YK, Chang HM, Yook JH, et al. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer. 2013;108:1245–51. https://doi.org/10.1038/bjc.2013.86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆). Ann Oncol. 2021;32:368–74. https://doi.org/10.1016/j.annonc.2020.11.017.

Article  CAS  PubMed  Google Scholar 

Kodera Y, Yoshida K, Kochi M, et al. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer. 2023;26:1063–8. https://doi.org/10.1007/s10120-023-01419-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang Y-K, Kim H-D, Yook JH, et al. Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: final survival outcomes of the randomized phase 3 PRODIGY trial. J Clin Oncol. 2023;41:S4067. https://doi.org/10.1200/JCO.2023.41.16_suppl.40.

Article  Google Scholar 

Zhang X, Li Z, Liang H, et al. LBA78 overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: an updated analysis of RESOLVE trial. Ann Oncol. 2023;34:S1318–9. https://doi.org/10.1016/j.annonc.2023.10.079.

Article  Google Scholar 

Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492–502. https://doi.org/10.1007/s10120-020-01136-7.

Article  CAS  PubMed  Google Scholar 

Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Article  CAS  PubMed  Google Scholar 

NCCN Guidelines Version 1 (2023) Gastric Cancer. 2023.

Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21:68–73. https://doi.org/10.1007/s10120-017-0701-1.

Article  PubMed  Google Scholar 

Kim HD, Lee JS, Yook JH, et al. Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study. Gastric Cancer. 2022;25:170–9. https://doi.org/10.1007/s10120-021-01243-z.

Article  CAS  PubMed  Google Scholar 

Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25:2107–16. https://doi.org/10.1200/jco.2006.09.5224.

Article  PubMed  Google Scholar 

Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol. 2010;25:512–8. https://doi.org/10.1111/j.1440-1746.2009.06106.x.

Article  PubMed  Google Scholar 

Cimavilla Román M, de la Serna HC, Loza Vargas LA, et al. Endoscopic ultrasound versus multidetector computed tomography in preoperative gastric cancer staging. Rev Esp Enferm Dig. 2017;109:761–7. https://doi.org/10.17235/reed.2017.4638/2016.

Article  PubMed  Google Scholar 

Nie RC, Yuan SQ, Chen XJ, et al. Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis. World J Surg Oncol. 2017;15:113. https://doi.org/10.1186/s12957-017-1176-6.

Article  PubMed  PubMed Central  Google Scholar 

Rosenbaum SJ, Stergar H, Antoch G, et al. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging. 2006;31:25–35. https://doi.org/10.1007/s00261-005-0031-3.

Article  CAS  PubMed  Google Scholar 

Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288–95. https://doi.org/10.1007/s00259-002-1029-5.

Article  CAS  PubMed  Google Scholar 

Wieder HA, Krause BJ, Herrmann K. PET and PET-CT in esophageal and gastric cancer. Methods Mol Biol. 2011;727:59–76. https://doi.org/10.1007/978-1-61779-062-1_5.

Article  PubMed  Google Scholar 

Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer. 2005;103:2383–90. https://doi.org/10.1002/cncr.21074.

Article  PubMed